Idiopathic (Essential) Hypertension – Pipeline Review, H2 2012

Idiopathic (Essential) Hypertension – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012', provides an overview of the Idiopathic (Essential) Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension. 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Idiopathic (Essential) Hypertension.
- A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Idiopathic (Essential) Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Idiopathic (Essential) Hypertension Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Idiopathic (Essential) Hypertension 7
Idiopathic (Essential) Hypertension Therapeutics under Development by Companies 9
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Idiopathic (Essential) Hypertension Therapeutics – Products under Development by Companies 14
Companies Involved in Idiopathic (Essential) Hypertension Therapeutics Development 15
Shionogi & Co., Ltd. 15
Novartis AG 16
Forest Laboratories, Inc. 17
Recordati S.p.A. 18
Sigma-Tau S.p.A. 19
XOMA Ltd. 20
Ahn-Gook Pharmaceutical Co., Ltd. 21
Aristo Pharmaceuticals Ltd. 22
Idiopathic (Essential) Hypertension – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
LCZ-696 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LCZ-696 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Rostafuroxin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
S-474474 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AG SCT101 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Telmisartan + Amlodipine + Hydrochlorothiazide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NanoActive Telmisartan - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NanoActive Candesartan Cilexetil - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AJH801 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Lercanidipine + Enalapril - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
nebivolol + valsartan - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
XOMA 985 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Idiopathic (Essential) Hypertension Therapeutics – Drug Profile Updates 45
Idiopathic (Essential) Hypertension Therapeutics - Dormant Products 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products Under Development for Idiopathic (Essential) Hypertension, H2 2012 7
Products under Development for Idiopathic (Essential) Hypertension – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Shionogi & Co., Ltd., H2 2012 15
Novartis AG, H2 2012 16
Forest Laboratories, Inc., H2 2012 17
Recordati S.p.A., H2 2012 18
Sigma-Tau S.p.A., H2 2012 19
XOMA Ltd., H2 2012 20
Ahn-Gook Pharmaceutical Co., Ltd., H2 2012 21
Aristo Pharmaceuticals Ltd., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Idiopathic (Essential) Hypertension Therapeutics – Drug Profile Updates 45
Idiopathic (Essential) Hypertension Therapeutics – Dormant Products 47

List of Figures
Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2012 7
Products under Development for Idiopathic (Essential) Hypertension – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28